Abstract
To estimate the cost per responder (CPR) of currently approved biologic and subsequent entry biologic (SEB) agents in achieving reductions in the Psoriasis Area and Severity Index (PASI) score at the end of the induction period of therapy for adult patients with moderate-to-severe plaque psoriasis in Canada.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
